Abstract:The human gut microbiota constitutes a complex community of microorganisms residing within the gastrointestinal tract, encompassing a vast array of species that play crucial roles in health and disease. The disease processes involved in chronic kidney disease (CKD) and end-stage kidney disease (ESKD) are now increasingly established to result in dysregulation of gut microbiota composition and function. Gut microbiota dysbiosis has been associated with poor clinical outcomes and all-cause mortality in patients with ESKD, particularly individuals receiving dialysis. Prior studies highlighted various factors that affect gut microbiota dysbiosis in CKD and ESKD. These include, but are not limited to, uraemic toxin accumulation, chronic inflammation, immune dysfunction, medications, and dietary restrictions and nutritional status. There is a lack of studies at present that focus on the evaluation of gut microbiota dysbiosis in the context of dialysis. Knowledge on gut microbiota changes in this context is important for determining their impact on dialysis-specific and overall outcomes for this patient cohort. More importantly, evaluating gut microbiota composition can provide information into potential targets for therapeutic intervention. Identification of specific microbial signatures may result in further development of personalised treatments to improve patient outcomes and mitigate complications during dialysis. Optimising gut microbiota through various therapeutic approaches, including dietary adjustments, probiotics, prebiotics, medications, and faecal transplantation, have previously demonstrated potential in multiple medical conditions. It remains to be seen whether these therapeutic approaches are effective within the dialysis setting. Our review aims to evaluate evidence relating to alterations in the gut microbiota of patients undergoing dialysis. A growing body of evidence pointing to the complex yet significant relationship which surrounds gut microbiota and kidney health emphasises the importance of gut microbial balance to improve outcomes for individuals receiving dialysis.

Smart oligopeptide gels: in situ formation and stabilization of gold and silver nanoparticles within supramolecular organogel networks.

The Interaction of Gut Microflora with Liver and Kidney Disease

Gut Microbiota in Patients Receiving Dialysis: A Review

Recent advances of gut microbiota in chronic kidney disease patients

Gut Dysbiosis and Its Role in the Anemia of Chronic Kidney Disease

The Role of the Gut Microbiota in Complications among Hemodialysis Patients

Gut microbiota regulates oxidative stress and inflammation: a double-edged sword in renal fibrosis

Gut microbiota and chronic kidney disease: implications for novel mechanistic insights and therapeutic strategies

Gut microbial metabolites SCFAs and chronic kidney disease

Superior humeral head migration occurs after a protocol designed to fatigue the rotator cuff: a radiographic analysis.

Microbiome–metabolome reveals the contribution of gut–kidney axis on kidney disease

The Immunomodulatory Effect of the Gut Microbiota in Kidney Disease

[Two cases of cutaneo-visceral loxoscelism].

Stabilizing Hypoxia-Inducible Factor to Manage Anemia in Chronic Kidney Disease: From Basic Theory to Clinical Study

The gut microbiota and its relationship with chronic kidney disease

Modulation of Pro- and Antifibrinolytic Properties of Human Peritoneal Mesothelial Cells by Transforming Growth Factor β1 (TGF- β1), Tumor Necrosis Factor α (TNF-α) and Interleukin β1 (IL-1β)

Hypoxia, HIF, and Associated Signaling Networks in Chronic Kidney Disease

Oral and intravenous iron treatment alter the gut microbiome differentially in dialysis patients

Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a document by the European Renal Best Practice board of the European Renal Association

The roles of gut microbiota and its metabolites in diabetic nephropathy